Loading...
Loading...
IMNN| Name | Value |
|---|---|
| Revenues | 727.2K |
| Cost of Revenue | 363.6K |
| Gross Profit | 363.6K |
| Operating Expense | 4,146.2K |
| Operating I/L | -4,146.2K |
| Other Income/Expense | 89.0K |
| Interest Income | 89.0K |
| Pretax | -4,057.2K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -4,057.2K |
Imunon, Inc. is a clinical stage biotechnology company specializing in DNA-based immunotherapies, vaccines, and directed chemotherapies. Their product pipeline includes GEN-1, a DNA-based immunotherapy for localized ovarian cancer treatment, and ThermoDox, a heat-activated liposomal encapsulation of doxorubicin for various cancer indications. Additionally, the company has two feasibility stage platform technologies for developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Imunon, Inc. generates revenue through the development and commercialization of these innovative treatments for cancer and other diseases.
